Nephrocare Health Services Appoints Prashant Vinodkumar Goenka as Chief Risk Officer
Nephrocare Health Services Limited designated Mr. Prashant Vinodkumar Goenka as Chief Risk Officer, effective April 03, 2026. He continues as CFO. Goenka, with over 20 years of financial services experience, joined the company on May 7, 2024.
The appointment of a key executive like a Chief Risk Officer can have a medium-term impact on the company's risk management strategies and overall governance framework.
The appointment of a Chief Risk Officer is a positive step for corporate governance and risk management, indicating a proactive approach by the company.
Nephrocare Health Services Limited has announced the designation of Mr. Prashant Vinodkumar Goenka, currently the Chief Financial Officer, as the Chief Risk Officer (CRO) of the company. This appointment is effective immediately, starting April 03, 2026. Mr. Goenka will continue to hold his existing responsibilities as CFO.
Mr. Goenka brings a wealth of experience to this new role. He has been with the company since May 7, 2024, overseeing finance, strategy, administration, secretarial, and technology functions. He holds a bachelor's degree in engineering (electrical and electronics) and a master's degree in science (economics) from BITS Pilani. Further, he obtained a master’s of business administration from the University of Chicago Booth School of Business, focusing on finance and strategic management. He is also a certified Six Sigma Master Black Belt and has over 20 years of experience in financial services, having worked with institutions like HSBC, Bank of America, and JP Morgan Chase across the USA, Philippines, and India.
The designation was approved by the Board of Directors through a circular resolution passed on April 03, 2026, in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Brief details as prescribed under SEBI Listing Regulations have been enclosed. The disclosure is also available on the company's website, www.nephroplus.com.
What to do with a filing like this
Nephrocare Health Services Limited filed this with the NSE as a statutory disclosure, categorised under key management changes. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Nephrocare Health Services Limited. Read the original for the full detail.